Frontlight ResearchEarly access
Haemophilia trials in South Korea
6 of 10 trials · From ClinicalTrials.gov, checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleSafety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
- Where
- Seoul
- Age
- 18 years and over
- People
- 173 worldwide
- Run by
- Pfizer
See details and how to joinNCT05568719 - Phase 3Taking peopleA Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
- Where
- Daegu
- Age
- 12 years and over
- People
- 360 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07416604 · EU 2025-522435-33-00 - Phase 3Taking peopleOpen-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
- Where
- Daegu, Seoul
- Age
- 1 year to 74 years
- People
- 245 worldwide
- Run by
- Pfizer
See details and how to joinNCT05145127 · EU 2022-500470-33-00 - Phase 3Taking peopleA Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A
- Where
- Gangdong-gu, Hwasun-gun
- Age
- 12 years and over
- People
- 138 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07416526 · EU 2025-522434-32-00 - Phase 3Taking peopleA Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
- Where
- Daegu, Seoul
- Age
- 1 year to 17 years
- People
- 100 worldwide
- Run by
- Pfizer
See details and how to joinNCT05611801 · EU 2022-500495-65-00 - Phase 3Taking peopleEfficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)
- Where
- Daegu, Seoul
- Age
- 18 years and over
- People
- 35 worldwide
- Run by
- CSL Behring
See details and how to joinNCT06003387 · EU 2023-509590-23-00